<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311429116</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311429116</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immune function and brain abnormalities in patients with systemic lupus erythematosus without overt neuropsychiatric manifestations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kozora</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">1</xref>
<xref ref-type="aff" rid="aff1-0961203311429116">2</xref>
<xref ref-type="aff" rid="aff1-0961203311429116">3</xref>
<xref ref-type="corresp" rid="corresp1-0961203311429116"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Filley</surname><given-names>CM</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">2</xref>
<xref ref-type="aff" rid="aff1-0961203311429116">3</xref>
<xref ref-type="aff" rid="aff1-0961203311429116">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Brown</surname><given-names>MS</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Miller</surname><given-names>DE</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Arciniegas</surname><given-names>DB</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">2</xref>
<xref ref-type="aff" rid="aff1-0961203311429116">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pelzman</surname><given-names>JL</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>West</surname><given-names>SG</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429116">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203311429116"><sup>1</sup>National Jewish Health, Denver, Colorado, USA; <sup>2</sup>Department of Neurology, University of Colorado Denver School of Medicine, Denver, Colorado, USA; <sup>3</sup>Department of Psychiatry, University of Colorado Denver School of Medicine, Denver, Colorado, USA; <sup>4</sup>Department of Radiology, University of Colorado Denver School of Medicine, Denver, Colorado, USA; <sup>5</sup>Department of Rheumatology, University of Colorado Denver School of Medicine, Denver, Colorado, USA; and <sup>6</sup>Denver Veterans Affairs Medical Center, Denver, Colorado, USA</aff>
<author-notes>
<corresp id="corresp1-0961203311429116">Elizabeth Kozora, PhD, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA Email: <email>kozorae@njhealth.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>402</fpage>
<lpage>411</lpage>
<history>
<date date-type="received"><day>7</day><month>4</month><year>2011</year></date>
<date date-type="accepted"><day>20</day><month>9</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> This study examined the relationship between immune, cognitive and neuroimaging assessments in subjects with systemic lupus erythematosus (SLE) without histories of overt neuropsychiatric (NP) disorders.</p>
<p><bold>Methods:</bold> In total, 84 subjects with nonNPSLE and 37 healthy controls completed neuropsychological testing from the American College of Rheumatology SLE battery. Serum autoantibody and cytokine measures, volumetric magnetic resonance imaging, and magnetic resonance spectroscopy data were collected on a subset of subjects.</p>
<p><bold>Results:</bold> NonNPSLE subjects had lower scores on measures of visual/complex attention, visuomotor speed and verbal memory compared with controls. No clinically significant differences between nonNPSLE patients and controls were found on serum measures of lupus anticoagulant, anticardiolipin antibodies, beta 2-glycoproteins, or pro-inflammatory cytokines (interleukin (IL)-1, IL-6, interferon alpha (IFN-alpha), and interferon gamma (IFN-gamma)). Higher scores on a global cognitive impairment index and a memory impairment index were correlated with lower IFN-alpha. Few associations between immune functions and neuroimaging parameters were found.</p>
<p><bold>Conclusions:</bold> Results indicated that nonNPSLE patients demonstrated cognitive impairment but not immune differences compared with controls. In these subjects, who were relatively young and with mild disease, no relationship between cognitive dysfunction, immune parameters, or previously documented neuroimaging abnormalities were noted. Immune measures acquired from cerebrospinal fluid instead of serum may yield stronger associations.</p>
</abstract>
<kwd-group>
<kwd>autoantibodies</kwd>
<kwd>cognition</kwd>
<kwd>cytokines</kwd>
<kwd>lupus</kwd>
<kwd>neuroimaging</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311429116"><title>Background</title>
<p>Cognitive dysfunction is common in over 50% of systemic lupus erythematosus (SLE) patients with active neurological and psychiatric disorders. Even in the absence of overt neuropsychiatric (NP) symptoms, cognitive dysfunction has been reported in 25–50% of patients with SLE.<sup><xref ref-type="bibr" rid="bibr1-0961203311429116">1</xref></sup> In the first cohort of 51 nonNPSLE subjects studied by our group, 31% demonstrated mild cognitive dysfunction (MCD-SLE), a significantly higher percentage than among healthy comparison subjects.<sup><xref ref-type="bibr" rid="bibr2-0961203311429116">2</xref></sup> Specific deficits in the domains of attention, fluency, and learning were noted. In later studies with two new nonNPSLE cohorts, 23% and 21% had MCD-SLE, respectively.<sup><xref ref-type="bibr" rid="bibr3-0961203311429116">3</xref>,<xref ref-type="bibr" rid="bibr4-0961203311429116">4</xref></sup></p>
<p>In SLE patients with overt NP involvement, pathogenic mechanisms have been separated based on the type of NP presentation.<sup><xref ref-type="bibr" rid="bibr5-0961203311429116">5</xref>,<xref ref-type="bibr" rid="bibr6-0961203311429116">6</xref></sup> For example, in patients with diffuse manifestations (for example, psychosis and depression), autoantibodies directed to central nervous system (CNS) antigens have been proposed as important pathogenic factors. In these cases, immunologically mediated neuronal cell injury is hypothesized to be caused by a variety of autoantibodies. Autoantibodies associated with NP activity in SLE include anti-neuronal antibodies, brain cross-reactive lymphocytotoxic antibodies, antiphospholipid (aPL) antibodies including lupus anticoagulant (LAC) and anticardiolipins (aCL), and antibodies to ribosomal proteins (anti-ribosomal P). In contrast to diffuse disease, focal CNS presentations in SLE such as stroke syndromes, seizures, movement disorders, and myelopathy have been postulated to be due to ischemia. These cases appear to separate out as being secondary to hypercoagulability (for example, related to antiphospholipid antibodies) and less commonly to vasculitis involving the CNS.</p>
<p>The mechanisms underlying MCD-SLE and brain abnormalities in SLE remain incompletely characterized. Several possible contributors to mild neuropsychological dysfunction in this population that have been explored but not consistently implicated include disease severity, medications, emotional distress (including depression), fatigue, and pain.<sup><xref ref-type="bibr" rid="bibr1-0961203311429116">1</xref></sup> Immune-mediated neuronal injury is thought to be the primary mechanism for some types of diffuse NP symptoms in SLE, including MCD.<sup>28</sup> However, none of the autoantibodies studied to date (anti-neuronal antibodies, brain cross-reactive lymphocytotoxic antibodies, aPL, and N-methyl-D-aspartate (NMDA) receptor antibodies are consistently associated with MCD-SLE except aPL.<sup><xref ref-type="bibr" rid="bibr2-0961203311429116">2</xref></sup><sup>,7–10</sup></p>
<p>Cytokine dysregulation and inflammation are other processes that may underlie MCD-SLE. A growing body of evidence suggests that neuronal, endocrine, and immune cells share common communication molecules and receptors, and are functionally linked to form a brain–endocrine–immune axis that integrates physiological responses.<sup><xref ref-type="bibr" rid="bibr11-0961203311429116">11</xref>,<xref ref-type="bibr" rid="bibr12-0961203311429116">12</xref></sup> Pro-inflammatory cytokines are elevated in the setting of acute anti-inflammatory responses in both animal models and clinical studies of rheumatoid arthritis (RA) and SLE.<sup>13–16</sup> Patients with active NPSLE demonstrate elevations of interleukin-1 (IL-1), IL-6, interferon alpha (IFN-alpha), and tumor necrosis factor (TNF) in cerebrospinal fluid (CSF).<sup>17–23</sup> Few studies have explored peripheral cytokine activity in relation to neuropsychological functioning in SLE. In our prior study, we did not find differences in plasma levels of IL-6 between 15 nonNPSLE, 15 RA, and 15 healthy control subjects;<sup><xref ref-type="bibr" rid="bibr24-0961203311429116">24</xref></sup> however, IL-6 contributed uniquely to measures of learning beyond the effects of depression, prednisone therapy, and various hormonal measures. The findings also suggest that the relationship between plasma IL-6 production and cognitive functioning may be quadratic (as an inverted U-shaped function) whereby moderate levels facilitate, but very low and very high levels disrupt, learning capacity. In another study, inflammation measured via c-reactive protein was associated with deficits in information processing in patients with SLE.<sup><xref ref-type="bibr" rid="bibr25-0961203311429116">25</xref></sup></p>
<p>In a subsequent cohort of nonNPSLE patients, neuropsychological evaluation demonstrated cognitive dysfunction in 21% of this sample.<sup><xref ref-type="bibr" rid="bibr26-0961203311429116">26</xref></sup> We also examined magnetic resonance imaging (MRI) and MR spectroscopy (MRS) in this group, and observed no significant differences in total brain, gray matter, or white matter (WM) volumes, or in frontal WM N-acetylaspartate/creatine (NAA/Cr) between the nonNPSLE group and healthy controls. However, the nonNPSLE group had significantly increased choline/creatine (Ch/Cr) in frontal WM that correlated with cognitive impairment.<sup><xref ref-type="bibr" rid="bibr27-0961203311429116">27</xref></sup> No cerebral atrophy or WM axonal damage was evident. In a recent analysis of selected subjects in this cohort, an association between reduced memory and lower NAA/Cr in the right hippocampus suggested neuronal damage in nonNPSLE patients with very mild and early disease.<sup><xref ref-type="bibr" rid="bibr28-0961203311429116">28</xref></sup> Alterations in glutamate and glutamine (Glu and Gln, respectively, and Glx collectively) quantified as Glx/Cr further indicate that early metabolic changes in the hippocampus of nonNPSLE patients are related to memory impairment.<sup><xref ref-type="bibr" rid="bibr28-0961203311429116">28</xref></sup></p>
<p>In this study, a variety of serum autoantibodies (aPL, aCL, and beta-2 glycoprotein (B2-GPI)) and pro-inflammatory cytokines (IL-1, IL-6, IFN-alpha, and interferon gamma (IFN-gamma)) were measured in nonNPSLE patients to explore relationships between these parameters and neuroimaging findings in terms of cognitive dysfunction and brain abnormalities.</p></sec>
<sec id="sec2-0961203311429116" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203311429116" sec-type="subjects"><title>Subjects</title>
<p>For this investigation, 84 subjects with nonNPSLE and 37 healthy controls were enrolled between August 2004 and April 2009. This study was reviewed and approved by the Colorado Multiple Institutional Review Board and the Institutional Review Board at National Jewish Health (NJH). The SLE subjects were obtained from a pool of patients seen at the University of Colorado Hospital (UCH), NJH, and local rheumatology clinics. SLE subjects with possible cerebral damage before disease onset (head trauma, stroke, degenerative disease, neoplasm, or metabolic or toxic exposure), major substance abuse, and major psychopathology were excluded using an NP checklist completed by their rheumatologist. In addition, all subjects were screened by a research assistant using a 10–15 min interview<sup><xref ref-type="bibr" rid="bibr2-0961203311429116">2</xref></sup> to ensure inclusion/exclusion criteria, and were administered the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) psychiatric interview to ensure that none had current depression.<sup><xref ref-type="bibr" rid="bibr29-0961203311429116">29</xref></sup></p>
<p>All patients with SLE fulfilled revised criteria as defined by the American College of Rheumatology (ACR)<sup><xref ref-type="bibr" rid="bibr30-0961203311429116">30</xref></sup> and were 18–50 years of age. SLE disease activity was measured by the patient’s rheumatologist prior to study enrollment using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).<sup><xref ref-type="bibr" rid="bibr31-0961203311429116">31</xref></sup> After inclusion criteria were confirmed, participants with SLE completed a standardized neurological examination, the Neurological Rating Scale (NRS),<sup><xref ref-type="bibr" rid="bibr32-0961203311429116">32</xref></sup> administered by a board-certified subspecialist in Behavioral Neurology and Neuropsychiatry to rule out any significant neurological examination findings.</p>
<p>Control subjects were similarly screened for neurological, psychiatric, and medical disorders before enrollment, and were selected to match the demographics of the patients with SLE. In total, 142 patients with SLE were screened for inclusion and 58 were excluded due to failure to meet ACR-SLE criteria, overt neuropsychiatric disorders, or MRI ineligibility. Some 56 controls were screened and 19 were excluded due to substance abuse.</p>
<p>After establishing that subjects met inclusion and exclusion criteria, participants underwent neuropsychological, neuroimaging, and immune assessments. Sample sizes for some measures were smaller than the complete 84 nonNPSLE and 37 controls because some subjects were subsequently entered into the supplemental study in which several of the neuroimaging and immune measures were performed.</p></sec>
<sec id="sec4-0961203311429116"><title>Procedures and measures</title>
<sec id="sec5-0961203311429116"><title>Neuropsychological testing</title>
<p>A test battery recommended by the ACR was administered, for which reliability and validity have been established.<sup><xref ref-type="bibr" rid="bibr3-0961203311429116">3</xref></sup> The following tests and scores were used in this battery. The <italic>WAIS-R Digit Symbol Subtest-total score</italic><sup><xref ref-type="bibr" rid="bibr33-0961203311429116">33</xref></sup> was used as a measure of psychomotor speed, concentration, and graphomotor abilities. The <italic>Trail Making Test-Part B-total time</italic><sup><xref ref-type="bibr" rid="bibr34-0961203311429116">34</xref></sup> was employed to measure psychomotor speed, attention, and cognitive sequencing. The <italic>Stroop Color and Word Test–Color–Word total score</italic><sup><xref ref-type="bibr" rid="bibr35-0961203311429116">35</xref></sup> was used to measure complex attention and ‘shifting’ of sets by naming color print for words written in different colors. The <italic>learning</italic> trials (summation of trials 1–5) and <italic>long delay free recall</italic> measures from the <italic>California Verbal Learning Test-Form II</italic> (CVLT)<sup><xref ref-type="bibr" rid="bibr36-0961203311429116">36</xref></sup> were selected to measure learning and recall of verbal material. The <italic>immediate</italic> and <italic>30-minute delayed recall</italic> of the <italic>Rey-Osterrieth Complex Figure Test</italic> (Rey-O)<sup><xref ref-type="bibr" rid="bibr37-0961203311429116">37</xref></sup> were selected to assess visual learning and memory. The <italic>WAIS-III Letter Number Sequencing Test-total score</italic> (LNST)<sup><xref ref-type="bibr" rid="bibr38-0961203311429116">38</xref></sup> was selected as a measure of auditory working memory. The <italic>Controlled Oral Word Association Test-total score</italic> and <italic>Animal Naming Test-total score</italic> (FAS, Animals)<sup><xref ref-type="bibr" rid="bibr39-0961203311429116">39</xref></sup> were selected as measures of letter and category verbal fluency; subjects generate as many words as possible that begin with a specified letter (F, A, or S) within 60 s, and produce the names of as many animals as possible within 60 s, respectively. The <italic>Finger Tapping Test-Dominant and Non-Dominant Hands</italic><sup><xref ref-type="bibr" rid="bibr34-0961203311429116">34</xref></sup> was used as a test of simple fine motor speed bilaterally. In addition, four tests were identified as sensitive to patients with SLE in our prior study<sup><xref ref-type="bibr" rid="bibr3-0961203311429116">3</xref></sup> and were included for analysis: the <italic>WAIS-R Block Design-total score</italic><sup><xref ref-type="bibr" rid="bibr33-0961203311429116">33</xref></sup> was obtained as a measure of visuoconstruction; the <italic>Paced Auditory Serial Addition Test-total score</italic> (PASAT)<sup><xref ref-type="bibr" rid="bibr40-0961203311429116">40</xref></sup> was used as a measure of rapid auditory information processing; the <italic>Digit Vigilance Test-total time</italic> (DVT)<sup><xref ref-type="bibr" rid="bibr34-0961203311429116">34</xref></sup> was employed to measure sustained visual attention; and the <italic>Category Test-total score</italic><sup><xref ref-type="bibr" rid="bibr34-0961203311429116">34</xref></sup> was used as a measure of general abstracting ability and analytic skills. The Wechsler Test of Adult Reading (WTAR) was administered to derive an estimated <italic>full-scale intelligence quotient</italic> (FSIQ)<sup><xref ref-type="bibr" rid="bibr41-0961203311429116">41</xref></sup>. The Beck Depression Inventory-II (BDI-II)<sup><xref ref-type="bibr" rid="bibr42-0961203311429116">42</xref></sup> was administered as a brief measure of psychological status. The Cognitive Failures Questionnaire (CFQ) was administered to evaluate self-reported cognitive problems.<sup><xref ref-type="bibr" rid="bibr43-0961203311429116">43</xref></sup></p>
<p>A cognitive impairment index (CII) was calculated utilizing 12 selected test scores for the ACR-SLE battery identified above.<sup><xref ref-type="bibr" rid="bibr3-0961203311429116">3</xref></sup> Each score was converted to a t-score using demographically corrected normative data.<sup>33–42</sup> T-scores below 40 were considered impaired. The ACR-CII ranges from 0–12, with a higher number representing greater cognitive impairment. A Memory Impairment Index (MII) was derived from the four learning and memory scores: learning trials and long delay free recall from the CVLT and immediate and 30-min delayed recall scores from the Rey-O. The four scores were converted to t-scores (<italic>M</italic> = 50, SD = 10) using available normative data for the tests. For both the CII and MII, each value below a t-score of 40 was considered impaired and received a score of 1. The CII and MII are both calculated as the sum of these four impairment scores, which range from 0 (none) to 4 (most impaired). The Verbal Memory score is the mean of the two CVLT measures above, and the Visual Memory score is the mean of the two Rey-O scores identified above.</p></sec>
<sec id="sec6-0961203311429116"><title>Immune assessments</title>
<p>Those subjects who agreed to participate in the immune study were instructed to visit the NJH clinic for a blood draw following informed consent. Two 10 ml tubes of blood were removed for research purposes by performing standard venipuncture via the antecubital vein. All blood draws were obtained by a licensed phlebotomist. One tube (10 ml of blood) was centrifuged (producing 4–5 ml of sera) for analysis of the proposed aPL antibodies and cytokines. Sera were stored at −70°C. All blood samples were coded to ensure participant confidentiality. LAC was screened using activated partial thromboplastin time (APTT), and dilute Russell’s viper venom time was performed and analyzed at Quest Diagnostics, Denver, CO, USA, using photo-optical clot detection. aCL were analyzed using enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of immunoglobulin (Ig)-G and IgM cardiolipin antibodies in human serum, and the analysis was performed according to the standard procedures by INOVA Diagnostics, San Diego, CA, USA. Activity of IgG and IgM were measured in units defined as the cardiolipin binding activity of 1ug/ml of IgG and IgM serum preparations. Classifications were presented according to previous standards.<sup><xref ref-type="bibr" rid="bibr44-0961203311429116">44</xref></sup> For the semi-quantitative detection of IgG and IgM B2-GPI antibodies in human serum, ELISA was performed and analyzed according to standard procedures by INOVA Diagnostics, San Diego, CA, USA. The Clinical Reference Laboratories at NJH completed the cytokine assays by the multiplex bead array method using the Luminex instrument in the reference laboratory and custom made kits (Linco, St. Louis, MO, USA) containing beads specific for IL-1, IL-6, IFN-alpha, and IFN-gamma.</p></sec>
<sec id="sec7-0961203311429116"><title>Neuroimaging assessment</title>
<p>MRI images were acquired with a research-dedicated 3.0-T GE MR SIGNA whole-body (long-bore) scanner (GE Healthcare, Waukesha, WI, USA) at the UCH Brain Imaging Center. Specific details of the MRI and MRS procedure and techniques have been previously published.<sup><xref ref-type="bibr" rid="bibr45-0961203311429116">45</xref>,<xref ref-type="bibr" rid="bibr46-0961203311429116">46</xref></sup></p></sec></sec>
<sec id="sec8-0961203311429116"><title>Statistical analysis</title>
<p>Analyses were conducted with the SAS statistical analysis package (version 9.2; SAS Institute Inc., Cary, NC, USA). Demographic variables were compared between the SLE and control groups using a Student <italic>t</italic>-test (for continuous variables) or Chi-square test (for categorical variables). For evaluation of group differences between nonNPSLE and controls, a non-parametric Wilcoxon’s Rank Sums test was used on continuous variables and Fisher’s Exact test was used on categorical variables. Spearman correlation coefficients were calculated between immune measures and cognitive and neuroimaging measures. Adjustments for multiple comparisons were not performed but will be considered in our discussion. For all analyses, two-tailed tests were used and <italic>p</italic>-values less than 0.05 were designated statistically significant.</p></sec></sec>
<sec id="sec9-0961203311429116" sec-type="results"><title>Results</title>
<sec id="sec10-0961203311429116"><title>Subject characteristics</title>
<p>There were no significant differences between groups on demographic variables including age, education level, sex distribution, or race/ethnicity (<xref ref-type="table" rid="table1-0961203311429116">Table 1</xref>). Health descriptors for the patients with SLE including length of diagnosis, SLEDAI total score, and percent of subjects on prednisone can also be found in <xref ref-type="table" rid="table1-0961203311429116">Table 1</xref>. Prednisone use was significantly higher in the patients with SLE compared with controls. Additional medications taken by the SLE subjects at the time of enrollment included non-steroidal anti-inflammatory drugs (NSAIDs; 36%), non-steroidal immunosuppressants (80%), anti-depressants (23%), anti-hypertensives (31%), drugs to modify anxiety and depression (30%), gastrointestinal medications (27%), thyroid medications (20%), and opioid analgesics (6%). The SLE group had a statistically higher proportion of subjects on all medications (<italic>p</italic> &lt; 0.05) except thyroid medications and analgesics. In total, 9% of healthy controls were taking thyroid medication but none were taking analgesics. The patients with SLE had significantly lower total NRS scores (<italic>p</italic> &lt; 0.001) compared with controls, and subsequent analysis indicated that patients with SLE had significantly lower scores (<italic>p</italic> = 0.003) on only the mentation and mood subset of the NRS. Participants with SLE had a history or presence of the following symptoms: malar rash (37.3%), discoid rash (13.3%), photosensitivity (54.2%), oral ulcers (32.5%), renal disorder (19.3%), hematologic disorder (41%), nonerosive arthritis (83.1%), positive antinuclear antibody (96.4%), immunologic disorder (68.7%), and/or pleuritis or pericarditis (22.9%).
<table-wrap id="table1-0961203311429116" position="float"><label>Table 1</label><caption><p>Demographic and health characteristics of subjects</p></caption>
<graphic alternate-form-of="table1-0961203311429116" xlink:href="10.1177_0961203311429116-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th align="center" colspan="2">nonNPSLE<hr/></th>
<th align="center" colspan="2">Control<hr/></th></tr>
<tr><th/>
<th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="6">Demographics</td></tr>
<tr>
<td> Age</td>
<td>36.74</td>
<td>8.71</td>
<td>34.95</td>
<td>8.63</td>
<td>0.2856</td></tr>
<tr>
<td> Education (years)</td>
<td>14.58</td>
<td>2.53</td>
<td>15.22</td>
<td>1.93</td>
<td>0.1474</td></tr>
<tr>
<td> Gender, % male</td>
<td align="center" colspan="2">4.8</td>
<td align="center" colspan="2">2.7</td>
<td>1.0000</td></tr>
<tr>
<td> Handedness, % right</td>
<td align="center" colspan="2">92.9</td>
<td align="center" colspan="2">91.9</td>
<td>1.0000</td></tr>
<tr>
<td> Ethnicity, % A/AA/C/H<sup><xref ref-type="table-fn" rid="table-fn1-0961203311429116">a</xref></sup></td>
<td colspan="2">3.6/19.0/63.1/14.3</td>
<td colspan="2">8.1/13.5/64.9/13.5</td>
<td>0.0672</td></tr>
<tr>
<td colspan="6">Health characteristics</td></tr>
<tr>
<td> Length of diagnosis (months)</td>
<td>90.21</td>
<td>78.72</td>
<td colspan="2">NA<sup><xref ref-type="table-fn" rid="table-fn2-0961203311429116">b</xref></sup></td>
<td/></tr>
<tr>
<td> SLEDAI<sup><xref ref-type="table-fn" rid="table-fn3-0961203311429116">c</xref></sup> total</td>
<td>5.13</td>
<td>5.37</td>
<td colspan="2">NA</td>
<td/></tr>
<tr>
<td> % on prednisone</td>
<td align="center" colspan="2">59.5</td>
<td colspan="2">0</td>
<td>&lt;0.0001</td></tr>
<tr>
<td colspan="6">Behavioral characteristics</td></tr>
<tr>
<td> BDI<sup><xref ref-type="table-fn" rid="table-fn4-0961203311429116">d</xref></sup> total score</td>
<td>9.42</td>
<td>7.05</td>
<td>3.70</td>
<td>5.23</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> CFQ<sup><xref ref-type="table-fn" rid="table-fn5-0961203311429116">e</xref></sup> total score</td>
<td>42.69</td>
<td>17.28</td>
<td>30.00</td>
<td>11.08</td>
<td>0.0002</td></tr>
<tr>
<td> Full-scale IQ</td>
<td>103.44</td>
<td>8.49</td>
<td>104.81</td>
<td>8.17</td>
<td>0.3999</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311429116"><label>a</label><p>Asian, African American, Caucasian, Hispanic.</p></fn>
<fn id="table-fn2-0961203311429116"><label>b</label><p>Not applicable.</p></fn>
<fn id="table-fn3-0961203311429116"><label>c</label><p>Systemic Lupus Erythematosus Disease Activity Index.</p></fn>
<fn id="table-fn4-0961203311429116"><label>d</label><p>Beck Depression Inventory-II.</p></fn>
<fn id="table-fn5-0961203311429116"><label>e</label><p>Cognitive Failures Questionnaire.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The SLE group had significantly higher depressive symptoms on the BDI-II and greater self-reported cognitive problems utilizing the CFQ, as noted in <xref ref-type="table" rid="table2-0961203311429116">Table 2</xref>. No significant differences were found in estimated FSIQ from the WTAR.
<table-wrap id="table2-0961203311429116" position="float"><label>Table 2</label><caption><p>Comparison of individual and composite neuropsychological test scores</p></caption>
<graphic alternate-form-of="table2-0961203311429116" xlink:href="10.1177_0961203311429116-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th align="center" colspan="2">nonNPSLE<hr/></th>
<th align="center" colspan="2">Control<hr/></th></tr>
<tr><th/>
<th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="6"><bold>Individual Cognitive Tests</bold></td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Digit Symbol</td>
<td>48.12</td>
<td>9.95</td>
<td>52.81</td>
<td>8.84</td>
<td>0.0177</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>LNST<sup>a</sup></td>
<td>50.68</td>
<td>9.80</td>
<td>55.57</td>
<td>9.57</td>
<td>0.0154</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Stroop<sup>b</sup></td>
<td>50.81</td>
<td>8.52</td>
<td>52.86</td>
<td>9.16</td>
<td>0.2576</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Trails B<sup>c</sup></td>
<td>50.17</td>
<td>10.80</td>
<td>52.03</td>
<td>9.02</td>
<td>0.3679</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>FAS<sup>d</sup></td>
<td>45.63</td>
<td>9.99</td>
<td>44.46</td>
<td>10.97</td>
<td>0.5024</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Animals<sup>e</sup></td>
<td>49.19</td>
<td>8.87</td>
<td>48.86</td>
<td>7.97</td>
<td>0.8156</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>CVLT<sup>f</sup> Learn</td>
<td>48.87</td>
<td>11.86</td>
<td>53.35</td>
<td>11.70</td>
<td>0.0415</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>CVLT Delay</td>
<td>47.39</td>
<td>12.99</td>
<td>51.76</td>
<td>11.68</td>
<td>0.0844</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Rey-O<sup>g</sup> Immediate</td>
<td>40.10</td>
<td>12.40</td>
<td>42.14</td>
<td>11.63</td>
<td>0.4706</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Rey-O Delay</td>
<td>38.31</td>
<td>12.67</td>
<td>40.62</td>
<td>10.83</td>
<td>0.3936</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Tapping<sup>h</sup> Dominant</td>
<td>50.68</td>
<td>10.67</td>
<td>51.81</td>
<td>9.31</td>
<td>0.6818</td></tr>
<tr>
<td><xref ref-type="table-fn" rid="table-fn6-0961203311429116">*</xref>Tapping Non-dominant</td>
<td>49.55</td>
<td>9.54</td>
<td>52.27</td>
<td>10.15</td>
<td>0.1864</td></tr>
<tr>
<td>Block Design</td>
<td>51.08</td>
<td>11.58</td>
<td>49.97</td>
<td>10.33</td>
<td>0.8838</td></tr>
<tr>
<td>PASAT<sup>i</sup></td>
<td>46.04</td>
<td>10.13</td>
<td>47.11</td>
<td>9.39</td>
<td>0.7404</td></tr>
<tr>
<td>DVT<sup>j</sup></td>
<td>49.29</td>
<td>9.88</td>
<td>53.84</td>
<td>7.79</td>
<td>0.0403</td></tr>
<tr>
<td>Category</td>
<td>45.96</td>
<td>12.02</td>
<td>48.81</td>
<td>10.70</td>
<td>0.3937</td></tr>
<tr>
<td colspan="6"><bold>Impairment Indices</bold></td></tr>
<tr>
<td> CII<sup>k</sup> (range 0–12)</td>
<td>2.50</td>
<td>2.25</td>
<td>2.00</td>
<td>1.72</td>
<td>0.3624</td></tr>
<tr>
<td> MII<sup>l</sup> (range 0–4)</td>
<td>1.45</td>
<td>1.33</td>
<td>1.11</td>
<td>1.26</td>
<td>0.1856</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0961203311429116"><label>*</label><p>Tests included in the CII. <sup>a</sup>Letter-Number Sequencing Test. <sup>b</sup>Stroop Color and Word Test. <sup>c</sup>Trail Making Test-Part B. <sup>d</sup>Verbal Fluency. <sup>e</sup>Category Fluency. <sup>f</sup>California Verbal Learning Test-II. <sup>g</sup>Rey-Osterrieth Complex Figure Test. <sup>h</sup>Finger Tapping Test. <sup>i</sup>Paced Auditory Serial Addition Test. <sup>j</sup>Digit Vigilance Test. <sup>k</sup>Cognitive Impairment Index. <sup>l</sup>Memory Impairment Index.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec11-0961203311429116"><title>Neuropsychological, neuroimaging, and immune results</title>
<p>Performance on visuomotor speed (Digit Symbol subtest), working memory (LNST), verbal learning (CVLT), and sustained visual attention (DVT) tasks was poorer in nonNPSLE patients compared with controls (<xref ref-type="table" rid="table2-0961203311429116">Table 2</xref>). <xref ref-type="fig" rid="fig1-0961203311429116">Figure 1</xref> demonstrates the percent impairment across the individual tests. In terms of summary scores, there was no significant difference on the CII or MII between SLE and control groups. Using the CII impairment criteria, 23% of the nonNPSLE patients and 18% of the healthy controls were cognitively impaired.
<fig id="fig1-0961203311429116" position="float"><label>Figure 1</label><caption><p>Percent impairment across groups on neuropsychological tests. LNST- Letter: Number Sequencing Test. Stroop: Stroop Color and Word Test. Trails B: Trail Making Test Part B. FAS: Verbal Fluency. Animals: Category Fluency. CVLT: California Verbal Learning Test-II. Rey-O: Rey-Osterrieth Complex Figure Test. Tapping: Finger Tapping Test. PASAT: Paced Auditory Serial Addition Test. DVT: Digit Vigilance Test.</p></caption><graphic xlink:href="10.1177_0961203311429116-fig1.tif"/></fig>
<fig id="fig2-0961203311429116" position="float"><label>Figure 2</label><caption><p>Percent elevations of cytokines and anti-phospholipids across groups. IFN-a- Interferon-alpha. IFN-y- Interferon-gamma. IL-1 B- Interleukin-1 Beta. IL-6- Interleukin-6. B2GP IgG- Beta-2 Glycoprotein Immunoglobulin G. B2GP IgM- Beta-2 Glycoprotein Immunoglobulin M. aCL IgG- Anticardiolipin Immunoglobulin G. aCL IgM- Anticardiolipin Immunoglobulin M. APTT- Activated Partial Thromboplastin Time.</p></caption><graphic xlink:href="10.1177_0961203311429116-fig2.tif"/></fig>
</p>
<p>A majority of the MRI and MRS measures in this cohort have been published previously.<sup><xref ref-type="bibr" rid="bibr27-0961203311429116">27</xref>,<xref ref-type="bibr" rid="bibr47-0961203311429116">47</xref></sup> In the present study, 64 nonNPSLE patients without cognitive impairment were compared with 20 subjects with MCD-SLE using the Wilcoxon Rank Sums Test; there were no significant differences between the two groups on right or left NAA/Cr, Ch/Cr or NAA+N-Acetylaspartylglutamic acid (NAAG)/CR. There was significantly lower brain volume (<italic>p</italic> = 0.0267) in the group with MCD-SLE when compared with the group of SLE subjects without cognitive impairment.</p>
<p>Some 62 patients with nonNPSLE and 37 healthy control subjects had immunological measures; the demographics and health characteristics of SLE subjects in this subgroup were similar to those of the group of 84 SLE subjects from which they were drawn. <xref ref-type="table" rid="table3-0961203311429116">Table 3</xref> presents the immune measure data of the SLE and healthy controls groups and the comparisons of the mean values from these groups on these measures. Due to the skewed data, medians and interquartile ranges (IQR) are also available for review. Results using mean and median data indicate that SLE patients were significantly higher than controls on IL-6 levels (<italic>p</italic> = 0.038); a trend in this direction was also observed for IFN-alpha levels (<italic>p</italic> = 0.09). The SLE group had relatively higher percentages of elevated autoimmune and immune measures compared with healthy controls, but there was no significant difference using Fisher’s Exact test. Notably, only one of the four SLE patients with elevated APTT demonstrated an elevated Russell’s viper venom time.
<table-wrap id="table3-0961203311429116" position="float"><label>Table 3</label><caption><p>Comparisons of immunological variables across groups</p></caption>
<graphic alternate-form-of="table3-0961203311429116" xlink:href="10.1177_0961203311429116-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th align="center" colspan="4">nonNPSLE<hr/></th>
<th align="center" colspan="4">Control<hr/></th></tr>
<tr><th/>
<th>M</th>
<th>SD</th>
<th>Mdn<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">b</xref></sup></th>
<th>IQR<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">c</xref></sup></th>
<th>M</th>
<th>SD</th>
<th>Mdn</th>
<th>IQR</th>
<th><italic>p</italic>-value<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">a</xref></sup></th></tr></thead>
<tbody align="left">
<tr>
<td>aCL<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">d</xref></sup> IgG<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">e</xref></sup></td>
<td>7.64</td>
<td>10.31</td>
<td>5.0</td>
<td>8.0</td>
<td>4.71</td>
<td>4.14</td>
<td>4.0</td>
<td>6.0</td>
<td>0.24</td></tr>
<tr>
<td>aCL IgM<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">f</xref></sup></td>
<td>5.77</td>
<td>10.75</td>
<td>2.0</td>
<td>7.0</td>
<td>1.85</td>
<td>2.46</td>
<td>1.0</td>
<td>3.0</td>
<td>0.11</td></tr>
<tr>
<td>APTT<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">g</xref></sup></td>
<td>30.36</td>
<td>7.45</td>
<td>28.9</td>
<td>5.4</td>
<td>28.94</td>
<td>3.13</td>
<td>28.3</td>
<td>3.4</td>
<td>0.58</td></tr>
<tr>
<td>B2-GPI<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">h</xref></sup> IgG</td>
<td>1.36</td>
<td>3.74</td>
<td>0.0</td>
<td>1.0</td>
<td>0.57</td>
<td>0.55</td>
<td>1.0</td>
<td>1.0</td>
<td>0.91</td></tr>
<tr>
<td>B2-GPI IgM</td>
<td>16.81</td>
<td>61.40</td>
<td>1.0</td>
<td>2.0</td>
<td>1.92</td>
<td>2.86</td>
<td>1.0</td>
<td>2.0</td>
<td>0.61</td></tr>
<tr>
<td>IFN-α<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">i</xref></sup></td>
<td>160.26</td>
<td>937.38</td>
<td>1.9</td>
<td>11.8</td>
<td>244.71</td>
<td>1386.5</td>
<td>0.0</td>
<td>1.2</td>
<td>0.09</td></tr>
<tr>
<td>IFN-γ<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">j</xref></sup></td>
<td>0.47</td>
<td>0.60</td>
<td>0.4</td>
<td>0.3</td>
<td>0.42</td>
<td>0.27</td>
<td>0.4</td>
<td>0.2</td>
<td>0.44</td></tr>
<tr>
<td>IL<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">k</xref></sup>-1 β<sup><xref ref-type="table-fn" rid="table-fn7-0961203311429116">l</xref></sup></td>
<td>1.30</td>
<td>2.44</td>
<td>0.4</td>
<td>1.3</td>
<td>1.38</td>
<td>3.25</td>
<td>0.2</td>
<td>0.7</td>
<td>0.45</td></tr>
<tr>
<td>IL-6</td>
<td>2.76</td>
<td>5.53</td>
<td>1.35</td>
<td>2.2</td>
<td>3.09</td>
<td>6.74</td>
<td>0.9</td>
<td>0.8</td>
<td>0.04</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0961203311429116"><p><sup>a</sup>Comparisons run with Non-parametric Wilcoxon’s Rank Sums Test. <sup>b</sup>Median. <sup>c</sup>Interquartile Range. <sup>d</sup>Anticardiolipin (<italic>n</italic> = 47 for SLE, <italic>n</italic> = 34 for Controls for mean/SD/Mdn and IQR only). <sup>e</sup>Immunoglobulin G. <sup>f</sup>Immunoglobulin M. <sup>g</sup>Activated Partial Thromboplastin Time. <sup>h</sup>Beta-2 Glycoprotein. <sup>i</sup>alpha. <sup>j</sup>Interferon gamma. <sup>k</sup>Interleukin. <sup>l</sup>Beta.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Within the SLE group, there was a significant correlation between higher IL-6 and higher prednisone dose (<italic>r</italic> = 0.27, <italic>p</italic> = 0.044), but there were no other significant relationships between demographics and health characteristics (duration of disease, SLEDAI total score, or BDI-II) and IL-6 and IFN-alpha. A trend relationship was noted between higher age and lower IFN-alpha (<italic>r</italic> = 0.21, <italic>p</italic> = 0.087).</p>
<p>There was no significant difference in percent of elevated immune measures between the cognitively impaired and non-cognitively impaired SLE patients. Correlations between IL-6 and IFN-alpha, composite cognitive scores (CII and MII, Visual and Verbal Memory), and individual neuropsychological tests were calculated using Spearman’s correlation coefficient. For 62 SLE patients, lower IFN-alpha was associated with higher CII (<italic>r</italic> = −0.41, <italic>p</italic> = 0.001), higher MII (<italic>r</italic> = −0.41, <italic>p</italic> = &lt;0.001), and lower Visual Memory (<italic>r</italic> = −0.38, <italic>p</italic> = 0.003) and Verbal Memory (<italic>r</italic> = −0.295, <italic>p</italic> = 0.02) scores. There was a trend for lower IFN-alpha to be associated with worse performance on the Stroop Color-Word (<italic>p</italic> = 0.089). Higher IL-6 was not associated with any of the composite neuropsychological scores, but was associated with lower performance on Trail Making Test-Part A (<italic>p</italic> = 0.008), and showed a trend relationship with lower CVLT learning score (<italic>r</italic> = −0.239; <italic>p</italic> = 0.061).</p>
<p>No correlations were found between the quantitative MRI measures (i.e. whole brain volume, WM, gray matter, number or volume of WM lesions), or the frontal MRS measures (Ch/Cr or NAA/Cr) or hippocampal measures published previously.<sup><xref ref-type="bibr" rid="bibr28-0961203311429116">28</xref></sup></p></sec></sec>
<sec id="sec12-0961203311429116" sec-type="discussion"><title>Discussion</title>
<p>This study set out to address the influence of peripheral immune function on the brain in SLE. Lower cognitive performance on measures of visuomotor speed, working memory, verbal learning, and sustained visual attention was observed in this sample of 84 nonNPSLE patients when compared with a group of 37 healthy subjects. These findings are consistent with our prior research<sup><xref ref-type="bibr" rid="bibr3-0961203311429116">3</xref></sup> and continue to support the presence of MCD among SLE patients without overt NP activity (for example, stroke, seizure, and psychosis/major depression). The prevalence of cognitive impairment in this sample was 23.8%, a frequency similar to our prior study using the same screening procedures, neuropsychological tests, and definition of impairment.<sup><xref ref-type="bibr" rid="bibr3-0961203311429116">3</xref></sup> However, the frequency of cognitive impairment among the healthy control subjects in this sample was 7/37 (18.9%), which is higher than the 12% observed in our prior study.<sup><xref ref-type="bibr" rid="bibr3-0961203311429116">3</xref></sup> We did not find a difference between the number of impaired ACR-SLE test scores in the SLE patients compared with controls. It is unclear why the controls in this study performed worse than other control groups screened with similar interviews and questionnaires, but it is possible there were unreported or undiagnosed medical problems. For example, two of the impaired controls were on thyroid medication, suggesting a possible history of hypothyroidism that negatively affected cognitive function. In addition to using more rigorously selected healthy controls, future studies that compare immune and cognitive parameters in subjects with inflammatory or autoimmune disorders other than SLE may be useful in identifying unique mechanisms of cognitive dysfunction in SLE. For example, in our prior study we were able to identify specific cognitive deficits in patients with SLE compared with patients with RA.<sup><xref ref-type="bibr" rid="bibr2-0961203311429116">2</xref></sup></p>
<p>Comparing the immune parameters (autoantibodies and pro-inflammatory cytokines) between our SLE and control subjects yielded relatively few findings and none that appeared clinically significant. There were no significant differences in mean values or percent elevated on measures of aPLs such as LAC and aCL. A minority of SLE patients demonstrated elevated aCL-IgG (4.26%), elevated aCL-IgM (10.64%), and elevated APTT (9.84%); there was no significant difference in the percent elevation of these aPL markers in SLE compared with healthy controls. These frequencies are relatively low compared with other SLE studies, and may be explained by our subject selection (i.e. patients without overt NP activity). In a study of 323 consecutive SLE patients, 39.3% were classified as having aPL, and aPL was significantly higher in SLE patients with overt NP activity.<sup><xref ref-type="bibr" rid="bibr48-0961203311429116">48</xref></sup> We did not find correlations between aPL and cognition, or differences between cognitively impaired and non-cognitively impaired SLE on levels of aPL, a finding consistent with some prior studies.<sup><xref ref-type="bibr" rid="bibr47-0961203311429116">47</xref></sup><sup>,49–51</sup> In contrast, several other studies have found an association between aPL and cognition in SLE patients, with and without NP activity, with similar health and demographic data to the subjects in our sample.<sup><xref ref-type="bibr" rid="bibr7-0961203311429116">7</xref>,<xref ref-type="bibr" rid="bibr9-0961203311429116">9</xref>,<xref ref-type="bibr" rid="bibr52-0961203311429116">52</xref>,<xref ref-type="bibr" rid="bibr53-0961203311429116">53</xref></sup> A relationship between persistently elevated aCL antibodies and cognitive dysfunction in SLE has also been reported,<sup><xref ref-type="bibr" rid="bibr52-0961203311429116">52</xref>,<xref ref-type="bibr" rid="bibr53-0961203311429116">53</xref></sup> and indicates the importance of longitudinal designs in exploring the role of aPLs in cognitive dysfunction. Thus, a longitudinal approach may be essential to our understanding of aCL activity and the progression of cognitive dysfunction and brain abnormalities in SLE.</p>
<p>Our results did indicate elevated IFN-alpha and IL-6 in the nonNPSLE patients compared with controls; however, the variance around the mean values in these groups rendered them insignificant. Lower IFN-alpha was related to a variety of global cognitive scores, memory scores, and individual tests of visuomotor speed and attention. This finding was unexpected, as higher IFN-alpha in CSF has been associated with NPSLE activity,<sup><xref ref-type="bibr" rid="bibr54-0961203311429116">54</xref></sup> and in other medical disorders such as hepatitis C IFN-alpha treatment has resulted in cognitive decline.<sup><xref ref-type="bibr" rid="bibr55-0961203311429116">55</xref></sup> Given the relatively weak correlations, our findings remain unremarkable and although they might suggest that peripheral IFN-alpha may act to suppress disease activity in the SLE brain, this appears an unlikely suggestion in light of these data.</p>
<p>In contrast to our expectation, elevated IL-6 was not related to a majority of the cognitive summary scores or individual tests. This finding differs from our initial study,<sup><xref ref-type="bibr" rid="bibr56-0961203311429116">56</xref></sup> yet there were no apparent differences in demographics or health characteristics between the subjects included in our current and prior SLE cohorts. Some controversy regarding the analysis of serum versus CSF cytokines exists, and it is possible that our reliance on serum cytokine levels explains, at least in part, the relatively limited findings for this study. For example, Trysberg and colleagues<sup><xref ref-type="bibr" rid="bibr57-0961203311429116">57</xref></sup> reported that serum IL-6 did not differ between SLE patients with and without NP syndromes, but observed that 86% of the SLE patients with NPSLE demonstrated intrathecal elevations of IL-6. Based on this observation, they suggested that primary systemic production of cytokines with subsequent passage to CSF is not the most likely mechanism by which these cytokines exert their adverse effects on the CNS. Many investigators support the hypothesis that systemic production of pro-inflammatory cytokines outside the CNS can have effects on the brain and cognition in inflammatory disorders including SLE,<sup><xref ref-type="bibr" rid="bibr23-0961203311429116">23</xref></sup> but this mechanism of pathogenesis has proven difficult to establish empirically.</p>
<p>Overall, our serum measures of various aPLs and pro-inflammatory cytokines did not show consistent abnormalities in patients with SLE compared with controls. In a previous study by our group, a similar conclusion was drawn regarding NMDA receptor antibodies (anti-NR2).<sup><xref ref-type="bibr" rid="bibr10-0961203311429116">10</xref></sup> Except for IFN-alpha, none of the autoantibodies (aPL or anti-NR2) or other cytokines measured in this study were related to cognitive dysfunction in our SLE cohort, and none of the immune measures were related to neuroimaging abnormalities. It is possible that selection of our patients with SLE (i.e. those without overt NP activity) may have limited our findings.</p>
<p>Evidence exists, however, to show that immune activity in the CSF is likely a better index of NP activity in SLE than serum measures of immune function.<sup><xref ref-type="bibr" rid="bibr5-0961203311429116">5</xref>,<xref ref-type="bibr" rid="bibr54-0961203311429116">54</xref></sup><sup>,58–60</sup> Our studies suggest that serum analysis is not useful for understanding the immunopathogenesis of cognitive dysfunction in SLE. Examination of the CSF would enable assessment of the integrity of the blood–brain barrier as well as the measurement of intrathecal immune activity including autoantibodies and a variety of soluble cytokines, chemokines, and matrix metalloproteases. The cascade of molecular changes in the brain that influence cognitive dysfunction in SLE may be optimally investigated by direct examination of the CSF.</p></sec>
</body>
<back>
<sec id="sec13-0961203311429116"><title>Funding</title>
<p>This work was supported by the National Institute of Musculoskeletal and Skin Diseases (Grant RO1 AR049152-02).</p></sec>
<sec id="sec14-0961203311429116"><title>Disclosure</title>
<p>The authors report no conflicts of interest.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311429116"><label>1.</label><citation citation-type="other"><comment/>Kozora E. Neuropsychological functioning in systemic lupus erythematosus. In: Morgan JE and Ricker JH, (eds.). <italic>Textbook of Clinical Neuropsychology</italic>. New York: Taylor and Francis, 2008, p. 636–649</citation></ref>
<ref id="bibr2-0961203311429116"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>LL</given-names></name><name><surname>West</surname><given-names>SG</given-names></name><name><surname>Kotzin</surname><given-names>BL</given-names></name></person-group>. <article-title>Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>2035</fpage>–<lpage>2045</lpage>.</citation></ref>
<ref id="bibr3-0961203311429116"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Ellison</surname><given-names>MC</given-names></name><name><surname>West</surname><given-names>S</given-names></name></person-group>. <article-title>Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2004</year>; <volume>51</volume>: <fpage>810</fpage>–<lpage>818</lpage>.</citation></ref>
<ref id="bibr4-0961203311429116"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Arciniegas</surname><given-names>DB</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>59</volume>: <fpage>1639</fpage>–<lpage>1646</lpage>.</citation></ref>
<ref id="bibr5-0961203311429116"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>SG</given-names></name><name><surname>Emlen</surname><given-names>W</given-names></name><name><surname>Wener</surname><given-names>MH</given-names></name><name><surname>Kotzin</surname><given-names>BL</given-names></name></person-group>. <article-title>Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests</article-title>. <source><italic>Am J Med</italic></source> <year>1995</year>; <volume>99</volume>: <fpage>153</fpage>–<lpage>163</lpage>.</citation></ref>
<ref id="bibr6-0961203311429116"><label>6.</label><citation citation-type="other"><comment>West SG. The Nervous System. In: Wallace DJ and Hahn BH, (eds.). <italic>Dubois' Lupus Erythematosus</italic>. 7th ed. Philadelphia: Lippincott, Williams &amp; Wilkins, 2007, p. 707–746</comment>.</citation></ref>
<ref id="bibr7-0961203311429116"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denburg</surname><given-names>SD</given-names></name><name><surname>Carbotte</surname><given-names>RM</given-names></name><name><surname>Ginsberg</surname><given-names>JS</given-names></name><name><surname>Denburg</surname><given-names>JA</given-names></name></person-group>. <article-title>The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus</article-title>. <source>J Int Neuropsychol Soc</source> <year>1997</year>; <volume>3</volume>: <fpage>377</fpage>–<lpage>386</lpage>.</citation></ref>
<ref id="bibr8-0961203311429116"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denburg</surname><given-names>SD</given-names></name><name><surname>Carbotte</surname><given-names>RM</given-names></name><name><surname>Denburg</surname><given-names>JA</given-names></name></person-group>. <article-title>Cognitive correlates of antiphospholipid antibody positivity in SLE [abstract]</article-title>. <source>Arthritis &amp; Rheum</source> <year>1993</year>; <volume>36</volume>: <fpage>S103</fpage>–<lpage>S103</lpage>.</citation></ref>
<ref id="bibr9-0961203311429116"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leritz</surname><given-names>E</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Minor</surname><given-names>M</given-names></name><name><surname>Reis-Jensen</surname><given-names>F</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name></person-group>. <article-title>Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus</article-title>. <source>J Clin Exp Neuropsychol</source> <year>2002</year>; <volume>24</volume>: <fpage>527</fpage>–<lpage>533</lpage>.</citation></ref>
<ref id="bibr10-0961203311429116"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>West</surname><given-names>SG</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><etal/></person-group>. <article-title>Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes</article-title>. <source>J Neurol Sci</source> <year>2010</year>; <volume>295</volume>: <fpage>87</fpage>–<lpage>91</lpage>.</citation></ref>
<ref id="bibr11-0961203311429116"><label>11.</label><citation citation-type="other"><comment>DeSouza ED. <italic>Neurobiology of cytokines</italic>. San Diego, 1993</comment>.</citation></ref>
<ref id="bibr12-0961203311429116"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name></person-group>. <article-title>Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition</article-title>. <source>Psychol Rev</source> <year>1998</year>; <volume>105</volume>: <fpage>83</fpage>–<lpage>107</lpage>.</citation></ref>
<ref id="bibr13-0961203311429116"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>al-Janadi</surname><given-names>M</given-names></name><name><surname>al-Balla</surname><given-names>S</given-names></name><name><surname>al-Dalaan</surname><given-names>A</given-names></name><name><surname>Raziuddin</surname><given-names>S</given-names></name></person-group>. <article-title>Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases</article-title>. <source>J Clin Immunol</source> <year>1993</year>; <volume>13</volume>: <fpage>58</fpage>–<lpage>67</lpage>.</citation></ref>
<ref id="bibr14-0961203311429116"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>MJ</given-names></name><name><surname>Maini</surname><given-names>RN</given-names></name></person-group>. <article-title>Anti-cytokine therapy in rheumatoid arthritis</article-title>. <source>Baillieres Clin Rheumatol</source> <year>1995</year>; <volume>9</volume>: <fpage>633</fpage>–<lpage>652</lpage>.</citation></ref>
<ref id="bibr15-0961203311429116"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linker-Israeli</surname><given-names>M</given-names></name><name><surname>Deans</surname><given-names>RJ</given-names></name><name><surname>Wallace</surname><given-names>DJ</given-names></name><name><surname>Prehn</surname><given-names>J</given-names></name><name><surname>Ozeri-Chen</surname><given-names>T</given-names></name><name><surname>Klinenberg</surname><given-names>JR</given-names></name></person-group>. <article-title>Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis</article-title>. <source>J Immunol</source> <year>1991</year>; <volume>147</volume>: <fpage>117</fpage>–<lpage>123</lpage>.</citation></ref>
<ref id="bibr16-0961203311429116"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AK</given-names></name></person-group>. <article-title>Cytokines play a central role in the pathogenesis of systemic lupus erythematosus</article-title>. <source>Med Hypotheses</source> <year>1992</year>; <volume>39</volume>: <fpage>356</fpage>–<lpage>359</lpage>.</citation></ref>
<ref id="bibr17-0961203311429116"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alcocer-Varela</surname><given-names>J</given-names></name><name><surname>Aleman-Hoey</surname><given-names>D</given-names></name><name><surname>Alarcon-Segovia</surname><given-names>D</given-names></name></person-group>. <article-title>Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers</article-title>. <source>Lupus</source> <year>1992</year>; <volume>1</volume>: <fpage>111</fpage>–<lpage>117</lpage>.</citation></ref>
<ref id="bibr18-0961203311429116"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirohata</surname><given-names>S</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name></person-group>. <article-title>Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement</article-title>. <source>Arthritis Rheum</source> <year>1990</year>; <volume>33</volume>: <fpage>644</fpage>–<lpage>649</lpage>.</citation></ref>
<ref id="bibr19-0961203311429116"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>TS</given-names></name><name><surname>Wang</surname><given-names>CR</given-names></name><name><surname>Jeng</surname><given-names>GW</given-names></name><etal/></person-group>. <article-title>The study of anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with systemic lupus erythematosus and central nervous system involvement</article-title>. <source>Autoimmunity</source> <year>1994</year>; <volume>18</volume>: <fpage>169</fpage>–<lpage>175</lpage>.</citation></ref>
<ref id="bibr20-0961203311429116"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>TH</given-names></name><name><surname>Tsai</surname><given-names>ST</given-names></name><etal/></person-group>. <article-title>Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections</article-title>. <source>Scand J Rheumatol</source> <year>1994</year>; <volume>23</volume>: <fpage>57</fpage>–<lpage>63</lpage>.</citation></ref>
<ref id="bibr21-0961203311429116"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shiozawa</surname><given-names>S</given-names></name><name><surname>Kuroki</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Hirohata</surname><given-names>S</given-names></name><name><surname>Ogino</surname><given-names>T</given-names></name></person-group>. <article-title>Interferon-alpha in lupus psychosis</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>417</fpage>–<lpage>422</lpage>.</citation></ref>
<ref id="bibr22-0961203311429116"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benveniste</surname><given-names>EN</given-names></name></person-group>. <article-title>Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action</article-title>. <source>Am J Physiol</source> <year>1992</year>; <volume>263</volume>: <fpage>C1</fpage>–<lpage>C16</lpage>.</citation></ref>
<ref id="bibr23-0961203311429116"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dellalibera-Joviliano</surname><given-names>R</given-names></name><name><surname>Dos Reis</surname><given-names>ML</given-names></name><name><surname>Cunha Fde</surname><given-names>Q</given-names></name><name><surname>Donadi</surname><given-names>EA</given-names></name></person-group>. <article-title>Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus</article-title>. <source>J Rheumatol</source> <year>2003</year>; <volume>30</volume>: <fpage>485</fpage>–<lpage>492</lpage>.</citation></ref>
<ref id="bibr24-0961203311429116"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Laudenslager</surname><given-names>M</given-names></name><name><surname>Lemieux</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>SG</given-names></name></person-group>. <article-title>Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients</article-title>. <source>J Int Neuropsychol Soc</source> <year>2001</year>; <volume>7</volume>: <fpage>745</fpage>–<lpage>754</lpage>.</citation></ref>
<ref id="bibr25-0961203311429116"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shucard</surname><given-names>JL</given-names></name><name><surname>Gaines</surname><given-names>JJ</given-names></name><name><surname>Ambrus</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Shucard</surname><given-names>DW</given-names></name></person-group>. <article-title>C-reactive protein and cognitive deficits in systemic lupus erythematosus</article-title>. <source>Cogn Behav Neurol</source> <year>2007</year>; <volume>20</volume>: <fpage>31</fpage>–<lpage>37</lpage>.</citation></ref>
<ref id="bibr26-0961203311429116"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neurometabolic abnormalities is associated with cognitive imairment indicate white matter damage in nonNPSLE patients</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>S813</fpage>–<lpage>S813</lpage>.</citation></ref>
<ref id="bibr27-0961203311429116"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filley</surname><given-names>CM</given-names></name><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>White matter microstructure and cognition in non-neuropsychiatric systemic lupus erytematosus</article-title>. <source>Cogn Behav Neurol</source> <year>2009</year>; <volume>22</volume>: <fpage>38</fpage>–<lpage>44</lpage>.</citation></ref>
<ref id="bibr28-0961203311429116"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Memory impairment associated with neurometabolic abnormalities of the hippocampus in patients with non-neuropsychiatric systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>598</fpage>–<lpage>606</lpage>.</citation></ref>
<ref id="bibr29-0961203311429116"><label>29.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name></person-group>. <source>Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV)</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Press, Inc.</publisher-name>, <year>1996</year>.</citation></ref>
<ref id="bibr30-0961203311429116"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr31-0961203311429116"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Caron</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name></person-group>. <article-title>Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr32-0961203311429116"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sipe</surname><given-names>JC</given-names></name><name><surname>Knobler</surname><given-names>RL</given-names></name><name><surname>Barheny</surname><given-names>SL</given-names></name><name><surname>Rice</surname><given-names>GP</given-names></name><name><surname>Panitch</surname><given-names>HS</given-names></name><name><surname>Oldstone</surname><given-names>MB</given-names></name></person-group>. <article-title>A neurologic rating scale (NRS) for use in multiple sclerosis</article-title>. <source>Neurology</source> <year>1984</year>; <volume>34</volume>: <fpage>1368</fpage>–<lpage>1372</lpage>.</citation></ref>
<ref id="bibr33-0961203311429116"><label>33.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group>. <source>Wechsler Adult Intelligence Scale - Revised Manual</source>. <publisher-loc>San Antonio, Texas</publisher-loc>: <publisher-name>Psychological Corporation, Inc.</publisher-name>, <year>1981</year>.</citation></ref>
<ref id="bibr34-0961203311429116"><label>34.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Reitan</surname><given-names>RM</given-names></name><name><surname>Wolfson</surname><given-names>D</given-names></name></person-group>. <source>The Halstead-Reitan neuropsychology test battery</source>. <publisher-loc>Tucson, AZ</publisher-loc>: <publisher-name>Neuropsychological Press</publisher-name>, <year>1988</year>.</citation></ref>
<ref id="bibr35-0961203311429116"><label>35.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>CJ</given-names></name></person-group>. <source>Stroop color and word test</source>. <publisher-loc>Chicago</publisher-loc>: <publisher-name>Stoelting</publisher-name>, <year>1978</year>.</citation></ref>
<ref id="bibr36-0961203311429116"><label>37.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Delis</surname><given-names>D</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Ober</surname><given-names>B</given-names></name></person-group>. <source>California verbal learning test-second edition</source>. <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>The Psychological Corporation</publisher-name>, <year>2000</year>.</citation></ref>
<ref id="bibr37-0961203311429116"><label>39.</label><citation citation-type="other"><comment>Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial: Professional Manual. Psychological Assessment Resources, Inc., 1995</comment>.</citation></ref>
<ref id="bibr38-0961203311429116"><label>57.</label><citation citation-type="other"><comment>Wechsler D. Wechsler Adult Intelligence Scale-Third Edition. Psychological Corporation, Inc., 1997</comment>.</citation></ref>
<ref id="bibr39-0961203311429116"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladsjo</surname><given-names>JA</given-names></name><name><surname>Schuman</surname><given-names>CC</given-names></name><name><surname>Evans</surname><given-names>JD</given-names></name><name><surname>Peavy</surname><given-names>GM</given-names></name><name><surname>Miller</surname><given-names>SW</given-names></name><name><surname>Heaton</surname><given-names>RK</given-names></name></person-group>. <article-title>Norms for letter and category fluency: demographic corrections for age, education and ethnicity</article-title>. <source>Assessment</source> <year>1999</year>; <volume>6</volume>: <fpage>147</fpage>–<lpage>178</lpage>.</citation></ref>
<ref id="bibr40-0961203311429116"><label>58.</label><citation citation-type="other"><comment>Gronwall DM. Paced auditory serial additional test: a measure of recovery from concussion. Percept Motor Skills. 1977; 44: 367–373</comment>.</citation></ref>
<ref id="bibr41-0961203311429116"><label>59.</label><citation citation-type="other"><comment>Wechsler DA. Weschler Test of Adult Reading. San Antonio: The Psychological Corporation; 2001</comment>.</citation></ref>
<ref id="bibr42-0961203311429116"><label>60.</label><citation citation-type="other"><comment>Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory-II. The Psychological Corporation, 1996</comment>.</citation></ref>
<ref id="bibr43-0961203311429116"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broadbent</surname><given-names>DE</given-names></name><name><surname>Cooper</surname><given-names>PF</given-names></name><name><surname>FitzGerald</surname><given-names>P</given-names></name><name><surname>Parkes</surname><given-names>KR</given-names></name></person-group>. <article-title>The Cognitive Failures Questionnaire (CFQ) and its correlates</article-title>. <source>Br J Clin Psychol</source> <year>1982</year>; <volume>21</volume>: <fpage>1</fpage>–<lpage>16</lpage>.</citation></ref>
<ref id="bibr44-0961203311429116"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>EN</given-names></name><name><surname>Chan</surname><given-names>JK</given-names></name><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Aber</surname><given-names>VR</given-names></name><name><surname>Gharavi</surname><given-names>AE</given-names></name><name><surname>Hughes</surname><given-names>GR</given-names></name></person-group>. <article-title>Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test</article-title>. <source>Arch Intern Med</source> <year>1986</year>; <volume>146</volume>: <fpage>2153</fpage>–<lpage>2156</lpage>.</citation></ref>
<ref id="bibr45-0961203311429116"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filley</surname><given-names>CM</given-names></name></person-group>. <article-title>Exploring white matter microstructure: new insights from diffusion tensor imaging</article-title>. <source>Neurology</source> <year>2009</year>; <volume>73</volume>: <fpage>1718</fpage>–<lpage>1719</lpage>.</citation></ref>
<ref id="bibr46-0961203311429116"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Emery</surname><given-names>CF</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Make</surname><given-names>B</given-names></name></person-group>. <article-title>Improved neurobehavioral functioning in emphysema patients following medical therapy</article-title>. <source>J Cardiopulm Rehabil Prev</source> <year>2010</year>; <volume>30</volume>: <fpage>254</fpage>–<lpage>259</lpage>.</citation></ref>
<ref id="bibr47-0961203311429116"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name></person-group>. <article-title>Cognitive dysfunction and white matter abnormalities in systemic lupus erythematosus</article-title>. <source>J Int Neuropsychol Soc</source> <year>2011</year>; <volume>17</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr48-0961203311429116"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanna</surname><given-names>G</given-names></name><name><surname>Bertolaccini</surname><given-names>ML</given-names></name><name><surname>Cuadrado</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies</article-title>. <source>J Rheumatol</source> <year>2003</year>; <volume>30</volume>: <fpage>985</fpage>–<lpage>992</lpage>.</citation></ref>
<ref id="bibr49-0961203311429116"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Walsh</surname><given-names>NM</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Cognitive impairment and autoantibodies in systemic lupus erythematosus</article-title>. <source>Br J Rheumatol</source> <year>1993</year>; <volume>32</volume>: <fpage>291</fpage>–<lpage>296</lpage>.</citation></ref>
<ref id="bibr50-0961203311429116"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlomagno</surname><given-names>S</given-names></name><name><surname>Migliaresi</surname><given-names>S</given-names></name><name><surname>Ambrosone</surname><given-names>L</given-names></name><name><surname>Sannino</surname><given-names>M</given-names></name><name><surname>Sanges</surname><given-names>G</given-names></name><name><surname>Di Iorio</surname><given-names>G</given-names></name></person-group>. <article-title>Cognitive impairment in systemic lupus erythematosus: a follow-up study</article-title>. <source>J Neurol</source> <year>2000</year>; <volume>247</volume>: <fpage>273</fpage>–<lpage>279</lpage>.</citation></ref>
<ref id="bibr51-0961203311429116"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waterloo</surname><given-names>K</given-names></name><name><surname>Omdal</surname><given-names>R</given-names></name><name><surname>Sjoholm</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow</article-title>. <source>J Neurol</source> <year>2001</year>; <volume>248</volume>: <fpage>595</fpage>–<lpage>602</lpage>.</citation></ref>
<ref id="bibr52-0961203311429116"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Hong</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name></person-group>. <article-title>A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>728</fpage>–<lpage>734</lpage>.</citation></ref>
<ref id="bibr53-0961203311429116"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Jameson-Shortall</surname><given-names>E</given-names></name><name><surname>Newman</surname><given-names>SP</given-names></name><name><surname>Hall-Craggs</surname><given-names>M</given-names></name><name><surname>Chinn</surname><given-names>R</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>A longitudinal study of anticardiolipin antibody levels and cognitive functioning in SLE</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>735</fpage>–<lpage>741</lpage>.</citation></ref>
<ref id="bibr54-0961203311429116"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>A</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name></person-group>. <article-title>Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus</article-title>. <source>J Biomed Biotechnol</source> <year>2010</year>; <volume>2010</volume>: <fpage>268436</fpage>–<lpage>268436</lpage>.</citation></ref>
<ref id="bibr55-0961203311429116"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>W</given-names></name><name><surname>Hilsabeck</surname><given-names>RC</given-names></name><name><surname>Hassanein</surname><given-names>TI</given-names></name></person-group>. <article-title>Cognitive dysfunction in chronic hepatitis C: a review</article-title>. <source>Dig Dis Sci</source> <year>2008</year>; <volume>53</volume>: <fpage>307</fpage>–<lpage>321</lpage>.</citation></ref>
<ref id="bibr56-0961203311429116"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>West</surname><given-names>SG</given-names></name><name><surname>Kotzin</surname><given-names>BL</given-names></name><name><surname>Julian</surname><given-names>L</given-names></name><name><surname>Porter</surname><given-names>S</given-names></name><name><surname>Bigler</surname><given-names>E</given-names></name></person-group>. <article-title>Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease</article-title>. <source>Arthritis Rheum</source> <year>1998</year>; <volume>41</volume>: <fpage>41</fpage>–<lpage>47</lpage>.</citation></ref>
<ref id="bibr57-0961203311429116"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trysberg</surname><given-names>E</given-names></name><name><surname>Carlsten</surname><given-names>H</given-names></name><name><surname>Tarkowski</surname><given-names>A</given-names></name></person-group>. <article-title>Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement</article-title>. <source>Lupus</source> <year>2000</year>; <volume>9</volume>: <fpage>498</fpage>–<lpage>503</lpage>.</citation></ref>
<ref id="bibr58-0961203311429116"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arinuma</surname><given-names>Y</given-names></name><name><surname>Yanagida</surname><given-names>T</given-names></name><name><surname>Hirohata</surname><given-names>S</given-names></name></person-group>. <article-title>Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>1130</fpage>–<lpage>1135</lpage>.</citation></ref>
<ref id="bibr59-0961203311429116"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>XY</given-names></name><name><surname>Zhu</surname><given-names>CQ</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>XX</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>YY</given-names></name></person-group>. <article-title>Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>689</fpage>–<lpage>695</lpage>.</citation></ref>
<ref id="bibr60-0961203311429116"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trysberg</surname><given-names>E</given-names></name><name><surname>Tarkowski</surname><given-names>A</given-names></name></person-group>. <article-title>Cerebral inflammation and degeneration in systemic lupus erythematosus</article-title>. <source>Curr Opin Rheumatol</source> <year>2004</year>; <volume>16</volume>: <fpage>527</fpage>–<lpage>533</lpage>.</citation></ref>
</ref-list>
</back>
</article>